TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25738784
Drug: Balanced protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced protein intake (BAL: 25% daily protein/meal × 4)
Study: 25738784
Drug: Skewed protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skewed protein intake (SKEW: 7:17:72:4% daily protein/meal)
Study: 15231376
Drug: alpha-tocopherol 50
Normalized name: (+)-alpha-tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-tocopherol 50 mg
Study: 15231376
Drug: beta-carotene 20
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-carotene 20 mg
Study: 11199705
Drug: Nd:YAP laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nd:YAP laser with an energy of 240 mJ, a pulse repetition rate of 10 Hz (with water spray)
Study: 11199705
Drug: High-speed dental
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-speed dental handpiece (with water spray)
Study: 9049526
Drug: Quinaprilat (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinaprilat (5 ml or 10 ml injection twice daily)
Study: 21067273
Drug: Group LS:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group LS: 20 mL of 0.25% levobupivacaine infiltration to the nephrostomy tract followed by intravenous saline infusion
Study: 17300593
Drug: Vildagliptin 100
Normalized name: vildagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 100 mg q.d. + Pioglitazone 30 mg q.d. (50/15 mg q.d.)
Study: 17300593
Drug: Pioglitazone 30
Normalized name: pioglitazone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 30 mg q.d. (monotherapy)
Study: 11149474
Drug: Oral 10
Normalized name: Syringe Oral 10cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 10 mg alendronate
Study: 10401948
Drug: Continuous Positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Positive Airway Pressure (CPAP) in low ventilation group (10 l/min)
Study: 8583073
Drug: Omeprazole (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (80 mg bolus and 40 mg/12 h i.v.)
Study: 8583073
Drug: Ranitidine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (50 mg/4 h i.v.)
Study: 2193242
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (Sandoglobulin, Sandoz) 400 mg/kg, two times with an interval of two weeks
Study: 31833543
Drug: IVCS +
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVCS + Antibiotics (amoxicillin, vancomycin, metronidazole, doxycycline/ciprofloxacin)
Study: 31833543
Drug: IVCS +
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVCS + Antibiotics
Study: 28492920
Drug: Intravitreous 0.5-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreous 0.5-mg ranibizumab therapy
Study: 25929985
Drug: Optimized usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized usual primary care PTSD Treatment (OUC)
Study: 8789548
Drug: Milk perfusion
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk perfusion (10 mL at 3 mL/min) in patients with cow's milk intolerance
Study: 1362031
Drug: HM175 vaccine
Normalized name: hepatitis A vaccine (inactivated) strain HM175 Injection [Havrix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HM175 vaccine (third dose)
Study: 6528959
Drug: Uniphylline, 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uniphylline, 600 mg once daily
Study: 6367749
Drug: usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: usual treatment
Study: 27026689
Drug: Intensive DMARD
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive DMARD therapy
Study: 27026689
Drug: Standard DMARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard DMARD therapy
Study: 23999998
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral cholecalciferol supplementation (140,000 IU/month)
Study: 11002232
Drug: RT-CHOP (radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT-CHOP (radiotherapy followed by six cycles of CHOP chemotherapy)
Study: 21851906
Drug: Pentoxifylline 400
Normalized name: pentoxifylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 400 mg
Study: 31593830
Drug: Matched molecularly
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Matched molecularly targeted agents (MTAs) classified into ESCAT tiers II, IIIA, IIIB, and IVA
Study: 27735021
Drug: Alprostadil 60
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprostadil 60 mg and α-lipoic acid 600 mg in 250 mL normal saline, intravenous drip once per day for 2 weeks
Study: 27735021
Drug: Tadalafil 5
Normalized name: tadalafil 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 5 mg orally, once per night for 2 weeks
Study: 20521272
Drug: GTFT 1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTFT 1.4 g/L
Study: 9001836
Drug: Mibefradil (6.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mibefradil (6.25, 12.5, 25, 50, or 100 mg/d)
Study: 1291697
Drug: Group behavioral
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group behavioral therapy
Study: 1291697
Drug: Cognitive-behavioral marital
Normalized name: barbital
DrugBank: Barbital (DB01483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral marital treatments
Study: 2951089
Drug: Human ultralente
Normalized name: INSULIN HUMAN ULTRALENTE 100 UNIT/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human ultralente insulin (6 U)
Study: 2951089
Drug: Bovine ultralente
Normalized name: INSULIN,ULTRALENTE,HUMAN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine ultralente insulin
Study: 30309276
Drug: Monthly health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly health coaching
Study: 20485203
Drug: BUD 400
Normalized name: Clove buds
DrugBank: Clove (DB10672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUD 400 microg twice daily for 1 month, then 200 microg twice daily for 5 months
Study: 20485203
Drug: BUD 100
Normalized name: Clove buds
DrugBank: Clove (DB10672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUD 100 microg twice daily
Study: 10936668
Drug: Acarbose (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (100 mg three times daily)
Study: 7590814
Drug: cA2 chimeric
Normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cA2 chimeric anti-TNF alpha antibody (1 mg/kg)
Study: 7590814
Drug: cA2 chimeric
Normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cA2 chimeric anti-TNF alpha antibody (10 mg/kg)
Study: 367480
Drug: Cyproheptadine without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproheptadine without behaviour therapy
Study: 367480
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with behaviour therapy
Study: 367480
Drug: Placebo without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo without behaviour therapy
Study: 27365521
Drug: Control (brushing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (brushing teeth and gargling with 0.9% sodium chloride solution or water)
Study: 30923036
Drug: Nivolumab/ipilimumab combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab/ipilimumab combination therapy
Study: 21546160
Drug: S(+)‐ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: S(+)‐ketamine infusion (100-hour continuous intravenous infusion at 10-20mg/h)
Study: 12691925
Drug: Topical NSAIDs
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical NSAIDs
Study: 9067299
Drug: Nalbuphine 10
Normalized name: nalbuphine 10 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 10 mg/70 kg
Study: 29097640
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment with sulphadoxine‐pyrimethamine (IPT‐SP) alone
Study: 24224515
Drug: Intranasal DEX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal DEX 2 μg·kg(‐1) (group D2)
Study: 22128226
Drug: Sildenafil (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (combined low-, medium-, high-dose)
Study: 24637559
Drug: Medium-dose sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose sildenafil
Study: 19243716
Drug: High-dose varenicline
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose varenicline (1 mg BID)
Study: 19243716
Drug: Low-dose varenicline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose varenicline (0.5 mg BID)
Study: 19243716
Drug: Low-dose varenicline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose varenicline (0.5 mg once daily)
Study: 19243716
Drug: High-dose varenicline
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose varenicline (for low-body-weight group)
Study: 17559730
Drug: Terbinafine 1%
Normalized name: Terbinafine 1% Topical application Gel/Jelly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 1% film-forming solution (FFS)
Study: 17559730
Drug: Terbinafine 1%
Normalized name: Terbinafine 1% Topical application Gel/Jelly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 1% cream (Lamisil)
Study: 9192123
Drug: Atenolol (25-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (25-100 mg)
Study: 6417728
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no drugs)
Study: 1327634
Drug: L-alanine infusion
Normalized name: L-alanine
DrugBank: Alanine (DB00160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-alanine infusion (0.70, 1.40, or 2.80 nmol/kg body weight over 4.5 min)
Study: 1327634
Drug: L-alanine infusion
Normalized name: L-alanine
DrugBank: Alanine (DB00160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-alanine infusion (11.2 mmol/kg body weight in male Wistar rats)
Study: 28939374
Drug: Intravenous corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous corticosteroids
Study: 7631609
Drug: Warfarin (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (n = 32)
Study: 7631609
Drug: Warfarin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin and Placebo
Study: 6107987
Drug: Somatostatin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (600 pg/ml) added to distending fluid during 3 test periods in 10 subjects
Study: 31464617
Drug: Wuzi Yanzong
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wuzi Yanzong pill
Study: 26449227
Drug: Diazepam (final
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (final dose 0.07 mg/kg)
Study: 11301566
Drug: Intramuscular progestin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular progestin therapy (medroxyprogesterone acetate)
Study: 11301566
Drug: Oral progestin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral progestin therapy (medroxyprogesterone acetate)
Study: 8165049
Drug: Fluoride supplement
Normalized name: Fluoride supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride supplement (0.013 mmol or 0.25 mg)
Study: 8877673
Drug: moexipril 7.5
Normalized name: moexipril 7.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: moexipril 7.5 mg/day (in addition to hydrochlorothiazide 25 mg/day)
Study: 8877673
Drug: verapamil SR
Normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: verapamil SR 180 mg/day (in addition to hydrochlorothiazide 25 mg/day)
Study: 8877673
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of moexipril or verapamil SR with low-dose hydrochlorothiazide
Study: 3777411
Drug: 1% methohexital
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% methohexital solution
Study: 1815115
Drug: 25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/kg methohexital
Study: 6222545
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate treatment
Study: 6222545
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy according to Hammerstein
Study: 17912104
Drug: Carboxymethylcellulose gel
Normalized name: carboxymethylcellulose Ophthalmic Gel
DrugBank: Carboxymethylcellulose (DB11059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboxymethylcellulose gel and Oral-B toothpaste (control)
Study: 10645799
Drug: PEM regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEM regimen (cisplatin 60 mg/m2 on day 1, etoposide 40 mg/m2 on days 1, 2, and 3, mitomycin-C 7 mg/m2 on day 1)
Study: 10645799
Drug: Long CF
Normalized name: californium Cf-249
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long CF regimen (cisplatin 8 mg/m2 on days 1-5, 8-12, 15-19, and 22-26, 5-fluorouracil 300 mg/m2 as a 24 h infusion or oral UFT-E 400 mg/m2 on days 1-28)
Study: 7438383
Drug: Aspirin (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (1.0 g daily)
Study: 21460508
Drug: Daily bathing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily bathing with chlorhexidine gluconate (CHG) using CHG-impregnated cloths
Study: 16790200
Drug: Intravenous abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous abciximab bolus
Study: 17330512
Drug: Tocotrienol-rich vitamin
Normalized name: tocotrienols / vitamin E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocotrienol-rich vitamin E (TRE) 80 mg
Study: 17330512
Drug: Tocotrienol-rich vitamin
Normalized name: tocotrienols / vitamin E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocotrienol-rich vitamin E (TRE) 160 mg
Study: 11112128
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (200 microg, twice a day for 7 or 8 days)
Study: 11712620
Drug: Risperidone (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (6 mg/day)
Study: 9169965
Drug: Risperidone (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (16 mg/day)
Study: 12870569
Drug: Haloperidol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (20 mg/day)
Study: 3782046
Drug: Haloperidol (flexible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (flexible dose)
Study: 29439973
Drug: DS-2969b (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-2969b (60 mg, 200 mg, 400 mg)
Study: 27400997
Drug: 50,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50,000 IU vitamin D weekly for 16 weeks
Study: 21993377
Drug: Self-administered intraperitoneal
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered intraperitoneal bemiparin (BM)
Study: 8595686
Drug: Lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2% (40 mg)
Study: 14980919
Drug: Thiopental 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental 0.5 mg/kg
Study: 11710599
Drug: Hyperfractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiation therapy (HFX RT) alone
Study: 11710599
Drug: Hyperfractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiation therapy (HFX RT) with concurrent low-dose, daily cisplatin (CDDP)
Study: 7791060
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (Voltaren Ophthalmic)
Study: 14594790
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg Fe (control)
Study: 7665066
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg Fe
Study: 14594790
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Fe
Study: 29728858
Drug: ceramide complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: ceramide complex cream
Study: 140084
Drug: placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo cream
Study: 23713836
Drug: context-focused therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: context-focused therapy
Study: 22226683
Drug: First two
Approvals — FDA: no, EMA: no, PMDA: no
Description: First two fractions of treatment
Study: 19100066
Drug: Thiazide diuretics
Normalized name: althiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide diuretics (n = 200)
Study: 10507245
Drug: Metrifonate 50
Normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate 50 mg tablet administered in fasting condition
Study: 10507245
Drug: Metrifonate 50
Normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate 50 mg tablet administered after high-fat/high-calorie breakfast
Study: 10507245
Drug: Metrifonate 80
Normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate 80 mg tablet administered at 8:00 a.m. after overnight fasting
Study: 10507245
Drug: Metrifonate 80
Normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate 80 mg tablet administered at 7:00 p.m. (7 h after lunch)
Study: 10507245
Drug: Metrifonate 80
Normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate 80 mg tablet administered at 10:00 p.m. (4 h after dinner)
Study: 10507245
Drug: Metrifonate administration
Normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate administration (all studies)
Study: 10507245
Drug: Metrifonate administration
Normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate administration with food
Study: 10507245
Drug: Metrifonate administration
Normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate administration at different times (morning vs evening)
Study: 6798601
Drug: Morphine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (10 mg/70 kg body weight)
Study: 27966722
Drug: Coconut oil
Normalized name: Coconut Oil
DrugBank: Coconut oil (DB14322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coconut oil (CO) 22.25 g
Study: 27966722
Drug: Coconut oleogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coconut oleogel (CG) 25 g
Study: 26421692
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual (TAU) for 8 weeks
Study: 30040817
Drug: Dose-dense doxorubicin-cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense doxorubicin-cyclophosphamide then paclitaxel
Study: 30040817
Drug: Doxorubicin-cyclophosphamide then
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin-cyclophosphamide then weekly paclitaxel
Study: 12720542
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone 400 mg/day
Study: 8951189
Drug: (+/‐)‐sotalol multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: (+/‐)‐sotalol multiple doses of 80 mg twice daily for 7 consecutive days
Study: 8951189
Drug: (+/‐)‐sotalol single
Approvals — FDA: no, EMA: no, PMDA: no
Description: (+/‐)‐sotalol single doses of 80 and 160 mg
Study: 22048129
Drug: 21 mg
Normalized name: aspirin 421 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 mg transdermal nicotine
Study: 17443126
Drug: 14 mg
Normalized name: iodine 0.14 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 mg transdermal nicotine
Study: 1956099
Drug: All transdermal
Normalized name: all-trans-retinol
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All transdermal nicotine doses
Study: 29229440
Drug: Doxycycline PEP
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline PEP (200 mg single oral dose within 24 hours after sex)
Study: 17992062
Drug: PABM-intervention (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: PABM-intervention (50 minutes of physical activity twice a week + 50 minutes of behavior modification once a week)
Study: 11885548
Drug: Full vegetable
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full vegetable fat milk (FVF) (3.5 g fat/dL; 100% vegetable fat from palm-, coconut- and soybean oil)
Study: 2197158
Drug: Dilevalol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilevalol (200 mg once daily)
Study: 6791204
Drug: Naltrexone 200
Normalized name: NALTREXONE 200 mg / TRIAMCINOLONE 6.5 mg SUBCUTANEOUS IMPLANT [Naltrexone]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 200 mg per day for 1 week
Study: 19923506
Drug: Systemic lidocaine
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic lidocaine infusion
Study: 16897236
Drug: Ulinastatin (6000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulinastatin (6000 units x kg(‐1) infusion started 1 h after surgery)
Study: 16897236
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no protease inhibitors infused)
Study: 13129862
Drug: Laser photocoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser photocoagulation treatment
Study: 11075308
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MF) administered by dry-powder inhaler (DPI)
Study: 11075308
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MF) administered by metered-dose inhaler with an alternate propellant (MDI-AP)
Study: 11075308
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MF) administered by intravenous (i.v.) route
Study: 11075308
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MF) administered by DPI (separate study with tritiated MF)
Study: 30662004
Drug: Kefir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kefir (400 mL/day for 4 weeks)